TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25586983

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (n=15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Customary care (Control group, n=13)
Number of subjects: 28
Study: 23218136

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60 min of walking at 60% peak oxygen uptake)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 13
Study: 21196070

Group type: EXPERIMENTAL
Intervention: Integrated AutoPulse-CPR (iA-CPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual CPR (M-CPR)
Number of subjects: 0
Study: 18435370

Group type: EXPERIMENTAL
Intervention: Nite White Excel 2Z
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rembrandt Xtra Comfort
Number of subjects: 46
Study: 21878067

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) in combination with enalapril
Number of subjects: 0
Study: 16152867

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (other methods of pain control)
Number of subjects: 49
Study: 11898915

Group type: EXPERIMENTAL
Intervention: Inactive SLE patients (group I, no IT); PPD1 = 8.4 +/- 2.3
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Inactive SLE patients (group II, with IT); PPD1 = 5.1 +/- 1.9
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Active SLE patients (group III, no IT); PPD1 = 1.4 +/- 0.9
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Active SLE patients (group IV, with IT); PPD1 = 0.6 +/- 0.5
Number of subjects: 145

Group type: COMPARATOR
Intervention: Controls; PPD1 = 9.4 +/- 3
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Group IV (active with IT); PPD2 = 0.3 +/- 0.3
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Group I (inactive no IT); PPD2 = 2.6 +/- 0.9
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Group II (inactive with IT); PPD2 = 3.1 +/- 0.8
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Group III (active no IT); PPD2 = 1.2 +/- 0.8
Number of subjects: 145

Group type: COMPARATOR
Intervention: Controls; PPD2 = 7.9 +/- 2.5
Number of subjects: 145
Study: 9674789

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Midodrine 20 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Midodrine (2.5, 10, or 20 mg)
Number of subjects: 25
Study: 8072201

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy followed by surgery
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy followed by irradiation
Number of subjects: 95
Study: 3239478

Group type: EXPERIMENTAL
Intervention: Copper IUDs (non-complicated use)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Copper IUDs (complicated use)
Number of subjects: 600
Study: 12525260

Group type: EXPERIMENTAL
Intervention: Maca 1500 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maca 3000 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30583542

Group type: EXPERIMENTAL
Intervention: Clean-burning liquefied petroleum gas (LPG) stove
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 27990507

Group type: EXPERIMENTAL
Intervention: 4.0 mm-long implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mm or longer implants in augmented bone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Short implants (4.0 mm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mm or longer mandibular implants
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Short maxillary implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mm or longer maxillary implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: Augmented group (10 mm or longer implants)
Number of subjects: 80
Study: 24588456

Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional palpation technique
Number of subjects: 40
Study: 23327881

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) administered once daily at a dose of 3 mg
Number of subjects: 19
Study: 20494927

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 2745
Study: 18076881

Group type: EXPERIMENTAL
Intervention: 10-Hz electroacupuncture (EA) stimulation of ST-29 (guilai)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Simple needle insertion
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2-Hz burst EA stimulation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10-Hz EA stimulation of ST-25 (tianshu)
Number of subjects: 80
Study: 16189764

Group type: EXPERIMENTAL
Intervention: HRE-ICC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HRE-NBI
Number of subjects: 28

Group type: COMPARATOR
Intervention: HRE alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Random biopsies
Number of subjects: 28
Study: 11823664

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (biweekly intravenous alpha-galactosidase A infusions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects (placebo)
Number of subjects: 26
Study: 10369625

Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycosides (ODA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dosing of aminoglycosides
Number of subjects: 0
Study: 7771004

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 monotherapy (20 micrograms)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy (Prostaglandin E1 20 micrograms plus lidocaine 1% 1 cc)
Number of subjects: 22
Study: 2335312

Group type: EXPERIMENTAL
Intervention: Induction with oxytocin infusion
Number of subjects: 93

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 93
Study: 387172

Group type: EXPERIMENTAL
Intervention: Gamgee‐lined hat
Number of subjects: 211

Group type: COMPARATOR
Intervention: No hat (Control)
Number of subjects: 211
Study: 31403668

Group type: EXPERIMENTAL
Intervention: Web-based HIV/STD risk reduction intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study: 30468951

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) continued after one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elastic compression stockings (ECS) discontinued after one year
Number of subjects: 0
Study: 28040237

Group type: EXPERIMENTAL
Intervention: Gum Elastic Bougie (GEB)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscopy (NI)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 134
Study: 26336604

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Trivalent control vaccine (TIV)
Number of subjects: 601
Study: 23843881

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at local acupoints on the affected wrist (PC‐7 to TW‐5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at distal acupoints (contralateral ankle, SP‐6 to LV‐4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham EA at nonacupoint locations on the affected wrist
Number of subjects: 0
Study: 21329513

Group type: EXPERIMENTAL
Intervention: Telephone consultations with complementing text-messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular patient-individual telephone consultations
Number of subjects: 0
Study: 18952082

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 127
Study: 17239945

Group type: EXPERIMENTAL
Intervention: Composite (Sinfony, 3M‐ESPE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ceramic (negative control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unfilled resin (positive control)
Number of subjects: 7
Study: 12714402

Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.15%
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2.0%
Number of subjects: 146
Study: 11213534

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 1936

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 1936
Study: 8615362

Group type: EXPERIMENTAL
Intervention: High-resistant starch (39 +/- 3 g/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-resistant starch (5 +/- 0.4 g/d)
Number of subjects: 11
Study: 1351126

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (group C, 10(5.5) tissue-culture infectious doses50)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ALVAC-RG (group B, 10(4.5) tissue-culture infectious doses50)
Number of subjects: 25

Group type: COMPARATOR
Intervention: HDC (6.52 international potency units per dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ALVAC-RG and HDC
Number of subjects: 25
Study: 3969876

Group type: EXPERIMENTAL
Intervention: Bretylium 2.5 mg/kg over 60 minutes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bretylium 5.0 mg/kg over 60 minutes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bretylium 10 mg/kg over 60 minutes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 29961346

Group type: EXPERIMENTAL
Intervention: Client-centred activities of daily living (CADL) intervention
Number of subjects: 10
Study: 30938654

Group type: EXPERIMENTAL
Intervention: 4 mini-implants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 mini-implants
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2 standard implants
Number of subjects: 120
Study: 26773737

Group type: EXPERIMENTAL
Intervention: Yoga (Blood Pressure Education Program [BPEP])
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combined program (COMBO)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Blood Pressure Education Program (BPEP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Yoga and BPEP combined
Number of subjects: 137
Study: 24690964

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.5 g per day of eicosapentaenoic + docosahexaenoic)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (corn oil ethyl esters)
Number of subjects: 78
Study: 22472515

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1,100 ppm F as NaF), 0.12% chlorhexidine gluconate rinse, and 0.05% NaF rinse
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 231
Study: 20152959

Group type: EXPERIMENTAL
Intervention: Preservative-free diclofenac sodium 0.1% (Voltaren ophtha SDU; Novartis Pharma)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Preserved diclofenac sodium 0.1% (Voltaren ophtha; Novartis Pharma)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Preserved ketorolac tromethamine 0.5% (Acular; Pharm Allergan)
Number of subjects: 102
Study: 17661245

Group type: EXPERIMENTAL
Intervention: Morning preparation
Number of subjects: 201

Group type: COMPARATOR
Intervention: Evening preparation
Number of subjects: 201
Study: 16128276

Group type: EXPERIMENTAL
Intervention: Genetically derived vaccine (20 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plasma pooled vaccine (3 microg)
Number of subjects: 40
Study: 12383815

Group type: EXPERIMENTAL
Intervention: Subthreshold infrared (810 nm) diode laser macular grid photocoagulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 50
Study: 9846796

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) and Perborate (1.9 g sodium perborate-monohydrate in 30 ml water)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorhexidine (0.12%)
Number of subjects: 12
Study: 8003060

Group type: EXPERIMENTAL
Intervention: Doxycycline for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amoxicillin plus probenecid for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ceftriaxone for 2 weeks
Number of subjects: 38
Study: 2553364

Group type: EXPERIMENTAL
Intervention: UFTM (UFT and mitomycin C); UFT: 30 g total dose, Mitomycin C: 48-60 mg total dose
Number of subjects: 140

Group type: COMPARATOR
Intervention: UFT alone (control)
Number of subjects: 140
Study: 794022

Group type: EXPERIMENTAL
Intervention: Meglumine calcium metrizoate
Number of subjects: 139

Group type: COMPARATOR
Intervention: Meglumine sodium diatrizoate
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 139
Study: 30650418

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (monthly intervention by palliative care specialists at home for 12 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 28235493

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided subcostal TAP block with 1.5mg/kg bupivacaine diluted with saline to a total volume of 40mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: No TAP block (Control Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided subcostal TAP block
Number of subjects: 50
Study: 27931247

Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 1072
Study: 24743295

Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV testing and counselling (PITC)
Number of subjects: 1772
Study: 21859900

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with gemcitabine 1000 mg/m² on days 1, 8, and 15 and cisplatin 70 mg/m² on day 2, every 28 days.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with gemcitabine and cisplatin as above.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (surgery alone).
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with cisplatin on day 2.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Both AC and control groups.
Number of subjects: 194
Study: 19111629

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study: 17894896

Group type: EXPERIMENTAL
Intervention: >= 101% increment of serum creatinine
Number of subjects: 646
Study: 15334421

Group type: EXPERIMENTAL
Intervention: FDG-PET scan in patients with FMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: FDG-PET scan in healthy controls
Number of subjects: 12
Study: 11473839

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (6 to 10 mL of 0.25% bupivacaine epidurally, followed by infusion at 3 to 5 mL/h for 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural morphine (2 to 3 mg morphine epidurally, followed by infusion at a rate of 0.2 mg/h)
Number of subjects: 50
Study: 9892913

Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 1 week
Number of subjects: 269

Group type: COMPARATOR
Intervention: 1% clotrimazole cream applied twice daily for 4 weeks
Number of subjects: 269
Study: 7996316

Group type: EXPERIMENTAL
Intervention: Self-retaining retractor
Number of subjects: 213

Group type: COMPARATOR
Intervention: No retractor (control group)
Number of subjects: 213
Study: 3291529

Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.005 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.015 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.025 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 1711753

Group type: EXPERIMENTAL
Intervention: Intralesional injection of bleomycin sulphate (1 unit/ml)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 36
Study: 71449

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Aprotinin ('Trasylol')
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 257
Study: 31523063

Group type: EXPERIMENTAL
Intervention: Early removal of silicone stents (2 weeks postoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard removal of silicone stents (6 weeks postoperatively)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 50
Study: 28965748

Group type: EXPERIMENTAL
Intervention: Pharmacist case finding and intervention program (Medication Therapy Management consultation, patient assessment, laboratory assessment, individualized CV risk assessment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26727706

Group type: EXPERIMENTAL
Intervention: High-frequency microfocal vibratory stimulation (Equistasi)
Number of subjects: 0
Study: 24603201

Group type: EXPERIMENTAL
Intervention: Combined social and physical environmental intervention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Social environmental intervention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Physical environmental intervention
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 412
Study: 22563215

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 300 U/kg before CABG
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (saline) before CABG
Number of subjects: 71
Study: 19017764

Group type: COMPARATOR
Intervention: Bed rest (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise training (exercise group)
Number of subjects: 16
Study: 17376257

Group type: EXPERIMENTAL
Intervention: UC enhanced with psychiatrist-enhanced PEP
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: UC enhanced with CBT-enhanced PEP
Number of subjects: 325

Group type: COMPARATOR
Intervention: UC
Number of subjects: 325

Group type: COMPARATOR
Intervention: PEP
Number of subjects: 325
Study: 15142088

Group type: EXPERIMENTAL
Intervention: Combined treatment with immediate implant and subepithelial connective tissue graft (test group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Single immediate implants (control group)
Number of subjects: 116
Study: 11446129

Group type: EXPERIMENTAL
Intervention: Intervention group (pharmacist intervention)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 323
Study: 9882085

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg tid
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ketoprofen 50 mg tid
Number of subjects: 183
Study: 8049819

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2500111

Group type: EXPERIMENTAL
Intervention: Desipramine (tricyclic antidepressant)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (5-HT reuptake inhibitor)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study: 29992857

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: PAD with CAD
Number of subjects: 13885

Group type: COMPARATOR
Intervention: PAD without CAD
Number of subjects: 13885
Study: 26939522

Group type: EXPERIMENTAL
Intervention: Cer‐Mg and hydrocortisone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cer‐Mg and emollient
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cer‐Mg cream
Number of subjects: 100
Study: 24957753

Group type: EXPERIMENTAL
Intervention: Sleep training program for children with ADHD, supervised by parents for 12 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sleep hygiene information for children with ADHD (control group).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sleep hygiene information for healthy children (control group).
Number of subjects: 40
Study: 23136274

Group type: EXPERIMENTAL
Intervention: Diagnostic and treatment package for malaria and pneumonia using rapid diagnostic tests (RDT)
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Presumptive treatment with anti-malarial drugs; artemisinin combination therapy (ACT)
Number of subjects: 4216
Study: 20498608

Group type: EXPERIMENTAL
Intervention: Individualized, multidisciplinary 12-week cardiac rehabilitation program
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (information session and follow-up care)
Number of subjects: 105
Study: 18564952

Group type: EXPERIMENTAL
Intervention: Chiropractic management
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pain clinic management
Number of subjects: 30
Study: 15766306

Group type: EXPERIMENTAL
Intervention: 20 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12216010

Group type: EXPERIMENTAL
Intervention: Stress Process Model
Number of subjects: 0
Study: 10028205

Group type: EXPERIMENTAL
Intervention: Multicomponent in-hospital smoking cessation intervention
Number of subjects: 0
Study: 9014675

Group type: EXPERIMENTAL
Intervention: TAPP repair
Number of subjects: 86

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: TPP repair
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TAPP and TPP repair
Number of subjects: 86
Study: 1353678

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.5 mg bolus i.v. followed by 0.5 mg infused over 30 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 6381770

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (n = 72)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care program (n = 74)
Number of subjects: 146
Study: 29074070

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Laryngopharyngeal Tube (SALT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No PPE
Number of subjects: 0
Study: 26420345

Group type: EXPERIMENTAL
Intervention: Collagen-coated transvaginal mesh
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional anterior colporrhaphy
Number of subjects: 138